 Nicholas Cost
Concepts (397)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 68 | 2026 | 412 | 16.670 |
Why?
| | Wilms Tumor | 36 | 2025 | 85 | 10.700 |
Why?
| | Testicular Neoplasms | 23 | 2023 | 113 | 8.730 |
Why?
| | Nephrectomy | 36 | 2026 | 158 | 6.480 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 14 | 2023 | 75 | 5.740 |
Why?
| | Lymph Node Excision | 13 | 2024 | 173 | 3.900 |
Why?
| | Carcinoma, Renal Cell | 18 | 2025 | 234 | 3.830 |
Why?
| | Rhabdoid Tumor | 7 | 2026 | 103 | 3.000 |
Why?
| | Lymph Nodes | 9 | 2023 | 502 | 2.480 |
Why?
| | Neoplasm Staging | 27 | 2026 | 1465 | 2.400 |
Why?
| | Urology | 8 | 2024 | 64 | 2.280 |
Why?
| | Child | 102 | 2026 | 22657 | 2.170 |
Why?
| | Urinary Bladder | 5 | 2024 | 194 | 2.090 |
Why?
| | Lower Urinary Tract Symptoms | 3 | 2025 | 59 | 2.030 |
Why?
| | Medical Oncology | 7 | 2023 | 332 | 2.010 |
Why?
| | Child, Preschool | 71 | 2026 | 11799 | 1.980 |
Why?
| | Orchiectomy | 8 | 2023 | 74 | 1.920 |
Why?
| | Urodynamics | 4 | 2025 | 47 | 1.910 |
Why?
| | Laparoscopy | 12 | 2024 | 475 | 1.880 |
Why?
| | Rhabdomyosarcoma | 5 | 2022 | 64 | 1.780 |
Why?
| | Hydronephrosis | 6 | 2019 | 35 | 1.760 |
Why?
| | Adolescent | 74 | 2026 | 22453 | 1.740 |
Why?
| | Infant | 61 | 2026 | 10039 | 1.740 |
Why?
| | Urinary Tract | 3 | 2025 | 49 | 1.720 |
Why?
| | Vincristine | 3 | 2024 | 140 | 1.630 |
Why?
| | Lymphatic Metastasis | 12 | 2022 | 334 | 1.560 |
Why?
| | Urologic Surgical Procedures | 8 | 2019 | 115 | 1.550 |
Why?
| | Urologists | 3 | 2017 | 17 | 1.520 |
Why?
| | Urologic Neoplasms | 4 | 2017 | 31 | 1.450 |
Why?
| | Radiotherapy | 2 | 2025 | 206 | 1.410 |
Why?
| | Male | 109 | 2026 | 72406 | 1.380 |
Why?
| | Humans | 159 | 2026 | 144957 | 1.380 |
Why?
| | Kidney Pelvis | 6 | 2015 | 21 | 1.370 |
Why?
| | Robotics | 6 | 2015 | 87 | 1.350 |
Why?
| | Pelvic Neoplasms | 3 | 2025 | 24 | 1.340 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2022 | 101 | 1.330 |
Why?
| | Prognosis | 25 | 2026 | 4293 | 1.280 |
Why?
| | Pediatrics | 7 | 2025 | 1115 | 1.250 |
Why?
| | Practice Patterns, Physicians' | 6 | 2024 | 1358 | 1.240 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2021 | 259 | 1.180 |
Why?
| | Organ Sparing Treatments | 4 | 2023 | 38 | 1.140 |
Why?
| | Doxorubicin | 2 | 2021 | 397 | 1.070 |
Why?
| | Ureteral Obstruction | 5 | 2015 | 62 | 1.070 |
Why?
| | Urinary Bladder Diseases | 2 | 2019 | 18 | 1.050 |
Why?
| | Kidney | 9 | 2023 | 1496 | 1.030 |
Why?
| | Retrospective Studies | 49 | 2026 | 17101 | 1.010 |
Why?
| | Female | 86 | 2026 | 78376 | 0.990 |
Why?
| | Tumor Burden | 6 | 2019 | 322 | 0.940 |
Why?
| | Young Adult | 36 | 2026 | 14126 | 0.930 |
Why?
| | Kidney Diseases, Cystic | 3 | 2021 | 24 | 0.890 |
Why?
| | Rhabdomyosarcoma, Embryonal | 2 | 2022 | 16 | 0.880 |
Why?
| | Nephrons | 9 | 2023 | 23 | 0.860 |
Why?
| | Biopsy | 6 | 2024 | 1077 | 0.840 |
Why?
| | Ribonuclease III | 3 | 2021 | 44 | 0.830 |
Why?
| | Sarcoma, Clear Cell | 3 | 2025 | 9 | 0.820 |
Why?
| | Mixed Tumor, Malignant | 1 | 2023 | 5 | 0.810 |
Why?
| | Sertoli-Leydig Cell Tumor | 3 | 2021 | 8 | 0.800 |
Why?
| | DEAD-box RNA Helicases | 3 | 2021 | 90 | 0.800 |
Why?
| | Surgeons | 4 | 2025 | 340 | 0.780 |
Why?
| | Hypospadias | 4 | 2011 | 31 | 0.780 |
Why?
| | Seminoma | 3 | 2021 | 20 | 0.760 |
Why?
| | Urologic Surgical Procedures, Male | 4 | 2018 | 32 | 0.740 |
Why?
| | Sarcoma | 3 | 2024 | 205 | 0.740 |
Why?
| | Leydig Cell Tumor | 3 | 2021 | 8 | 0.730 |
Why?
| | Spermatic Cord Torsion | 2 | 2013 | 7 | 0.730 |
Why?
| | Age Factors | 13 | 2025 | 3335 | 0.710 |
Why?
| | Surgical Oncology | 2 | 2025 | 30 | 0.710 |
Why?
| | Disease-Free Survival | 7 | 2022 | 769 | 0.710 |
Why?
| | Cryptorchidism | 2 | 2019 | 17 | 0.700 |
Why?
| | Paraganglioma | 1 | 2022 | 65 | 0.700 |
Why?
| | Pulmonary Blastoma | 1 | 2021 | 8 | 0.680 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 133 | 0.660 |
Why?
| | Pheochromocytoma | 2 | 2019 | 67 | 0.650 |
Why?
| | Follow-Up Studies | 19 | 2026 | 5417 | 0.650 |
Why?
| | Tomography, X-Ray Computed | 9 | 2021 | 2738 | 0.640 |
Why?
| | Neoplasms | 7 | 2025 | 2884 | 0.640 |
Why?
| | Molecular Targeted Therapy | 3 | 2025 | 434 | 0.630 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2024 | 1141 | 0.620 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 3 | 0.620 |
Why?
| | Infant, Newborn | 11 | 2023 | 6434 | 0.610 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 2 | 2017 | 5 | 0.600 |
Why?
| | Cystectomy | 1 | 2019 | 41 | 0.600 |
Why?
| | Smooth Muscle Myosins | 1 | 2019 | 7 | 0.600 |
Why?
| | Muscle Relaxation | 1 | 2019 | 28 | 0.590 |
Why?
| | Myosin Light Chains | 1 | 2019 | 28 | 0.590 |
Why?
| | Neoplasm Invasiveness | 7 | 2017 | 509 | 0.590 |
Why?
| | Retroperitoneal Space | 2 | 2024 | 18 | 0.580 |
Why?
| | Diagnostic Imaging | 3 | 2022 | 339 | 0.570 |
Why?
| | Fertility Preservation | 3 | 2024 | 53 | 0.570 |
Why?
| | Survival Rate | 12 | 2026 | 2092 | 0.570 |
Why?
| | Treatment Outcome | 27 | 2025 | 11695 | 0.560 |
Why?
| | Catheterization | 1 | 2019 | 183 | 0.560 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 63 | 0.550 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 6053 | 0.550 |
Why?
| | Health Care Surveys | 2 | 2017 | 539 | 0.550 |
Why?
| | von Hippel-Lindau Disease | 1 | 2018 | 12 | 0.550 |
Why?
| | Testicular Diseases | 1 | 2018 | 6 | 0.550 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 139 | 0.550 |
Why?
| | Specimen Handling | 1 | 2019 | 186 | 0.540 |
Why?
| | Calculi | 1 | 2018 | 16 | 0.540 |
Why?
| | Neoadjuvant Therapy | 4 | 2021 | 463 | 0.540 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2012 | 531 | 0.530 |
Why?
| | Orchiopexy | 3 | 2019 | 7 | 0.530 |
Why?
| | Risk Assessment | 11 | 2025 | 3676 | 0.520 |
Why?
| | Conservative Treatment | 1 | 2018 | 44 | 0.520 |
Why?
| | Kaplan-Meier Estimate | 6 | 2019 | 966 | 0.510 |
Why?
| | Radiation Exposure | 1 | 2017 | 63 | 0.510 |
Why?
| | Kidney Medulla | 1 | 2016 | 31 | 0.500 |
Why?
| | Cytodiagnosis | 1 | 2017 | 31 | 0.500 |
Why?
| | Frozen Sections | 1 | 2017 | 24 | 0.500 |
Why?
| | Critical Pathways | 1 | 2018 | 108 | 0.500 |
Why?
| | Angiomyolipoma | 1 | 2016 | 21 | 0.490 |
Why?
| | Lung Neoplasms | 3 | 2021 | 2642 | 0.480 |
Why?
| | Teratoma | 2 | 2017 | 120 | 0.480 |
Why?
| | Muscle Contraction | 1 | 2019 | 429 | 0.480 |
Why?
| | Postoperative Care | 1 | 2018 | 288 | 0.470 |
Why?
| | Cancer Survivors | 1 | 2021 | 327 | 0.470 |
Why?
| | Tuberous Sclerosis | 1 | 2016 | 56 | 0.470 |
Why?
| | Granuloma, Plasma Cell | 1 | 2015 | 12 | 0.470 |
Why?
| | Cause of Death | 2 | 2026 | 472 | 0.460 |
Why?
| | Pediatricians | 1 | 2016 | 121 | 0.450 |
Why?
| | Survival Analysis | 5 | 2019 | 1385 | 0.450 |
Why?
| | Robotic Surgical Procedures | 2 | 2015 | 182 | 0.450 |
Why?
| | Glomerular Filtration Rate | 4 | 2018 | 760 | 0.440 |
Why?
| | Abdominal Neoplasms | 2 | 2025 | 47 | 0.440 |
Why?
| | Adult | 25 | 2025 | 40506 | 0.440 |
Why?
| | SEER Program | 6 | 2026 | 224 | 0.430 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1958 | 0.430 |
Why?
| | Neurofibromatosis 1 | 2 | 2019 | 54 | 0.430 |
Why?
| | Adenoma | 1 | 2016 | 218 | 0.420 |
Why?
| | Prospective Studies | 11 | 2025 | 7997 | 0.420 |
Why?
| | Societies, Medical | 5 | 2025 | 887 | 0.420 |
Why?
| | Prostatic Neoplasms | 2 | 2019 | 978 | 0.410 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2012 | 2147 | 0.410 |
Why?
| | Hypertension | 1 | 2022 | 1264 | 0.400 |
Why?
| | Germ-Line Mutation | 3 | 2025 | 175 | 0.390 |
Why?
| | Acute-Phase Proteins | 1 | 2013 | 67 | 0.390 |
Why?
| | Lipocalins | 1 | 2013 | 35 | 0.390 |
Why?
| | Minimally Invasive Surgical Procedures | 4 | 2025 | 192 | 0.390 |
Why?
| | Ultrasonography | 5 | 2019 | 770 | 0.390 |
Why?
| | Databases, Factual | 5 | 2019 | 1486 | 0.380 |
Why?
| | Infertility | 2 | 2024 | 55 | 0.380 |
Why?
| | Ovarian Neoplasms | 3 | 2021 | 586 | 0.380 |
Why?
| | Radiation Protection | 1 | 2013 | 41 | 0.380 |
Why?
| | Patient Education as Topic | 1 | 2018 | 780 | 0.370 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2013 | 99 | 0.370 |
Why?
| | Combined Modality Therapy | 5 | 2025 | 1268 | 0.370 |
Why?
| | Biopsy, Needle | 1 | 2013 | 183 | 0.370 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 497 | 0.370 |
Why?
| | United States | 15 | 2026 | 15988 | 0.360 |
Why?
| | Glucose Transporter Type 1 | 1 | 2012 | 48 | 0.360 |
Why?
| | Multimodal Imaging | 1 | 2013 | 129 | 0.350 |
Why?
| | Carcinoma, Medullary | 2 | 2025 | 16 | 0.350 |
Why?
| | Multivariate Analysis | 5 | 2018 | 1540 | 0.340 |
Why?
| | Neoplasm Metastasis | 5 | 2019 | 695 | 0.340 |
Why?
| | Incidence | 7 | 2019 | 2883 | 0.340 |
Why?
| | Primary Prevention | 1 | 2013 | 220 | 0.340 |
Why?
| | Codon | 1 | 2011 | 94 | 0.340 |
Why?
| | Positron-Emission Tomography | 1 | 2013 | 343 | 0.330 |
Why?
| | Proline | 1 | 2011 | 83 | 0.330 |
Why?
| | Suburethral Slings | 1 | 2010 | 10 | 0.320 |
Why?
| | Vena Cava, Inferior | 1 | 2011 | 81 | 0.320 |
Why?
| | Seasons | 1 | 2013 | 556 | 0.320 |
Why?
| | Hernia, Ventral | 1 | 2010 | 22 | 0.310 |
Why?
| | Arginine | 1 | 2011 | 262 | 0.310 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 623 | 0.310 |
Why?
| | Sex Factors | 3 | 2024 | 2114 | 0.310 |
Why?
| | Temperature | 1 | 2013 | 679 | 0.310 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2010 | 44 | 0.310 |
Why?
| | Urinary Incontinence | 1 | 2010 | 64 | 0.300 |
Why?
| | Mouth Mucosa | 1 | 2009 | 88 | 0.300 |
Why?
| | Ureter | 4 | 2014 | 36 | 0.300 |
Why?
| | Campomelic Dysplasia | 1 | 2009 | 2 | 0.300 |
Why?
| | Dysgerminoma | 1 | 2009 | 7 | 0.300 |
Why?
| | Urethra | 2 | 2011 | 57 | 0.290 |
Why?
| | Angiogenesis Inhibitors | 1 | 2011 | 237 | 0.290 |
Why?
| | Skin Transplantation | 1 | 2009 | 85 | 0.290 |
Why?
| | Urolithiasis | 1 | 2009 | 11 | 0.290 |
Why?
| | Clitoris | 1 | 2009 | 9 | 0.290 |
Why?
| | Length of Stay | 4 | 2025 | 1337 | 0.290 |
Why?
| | SOX9 Transcription Factor | 1 | 2009 | 28 | 0.290 |
Why?
| | Recovery of Function | 1 | 2013 | 710 | 0.290 |
Why?
| | Brachytherapy | 2 | 2021 | 134 | 0.290 |
Why?
| | Bone Neoplasms | 1 | 2011 | 256 | 0.290 |
Why?
| | Venous Thrombosis | 1 | 2011 | 195 | 0.280 |
Why?
| | Attitude of Health Personnel | 1 | 2016 | 1186 | 0.280 |
Why?
| | Surgical Flaps | 1 | 2009 | 142 | 0.280 |
Why?
| | Time Factors | 8 | 2019 | 7183 | 0.270 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 866 | 0.260 |
Why?
| | Aged | 12 | 2025 | 25947 | 0.260 |
Why?
| | Neuroblastoma | 2 | 2025 | 174 | 0.250 |
Why?
| | Calcinosis | 1 | 2009 | 234 | 0.250 |
Why?
| | Middle Aged | 14 | 2025 | 35928 | 0.250 |
Why?
| | Health Promotion | 1 | 2013 | 774 | 0.240 |
Why?
| | Risk Factors | 8 | 2018 | 10792 | 0.240 |
Why?
| | Ureterocele | 2 | 2016 | 7 | 0.230 |
Why?
| | Postoperative Complications | 6 | 2025 | 2920 | 0.230 |
Why?
| | Survivorship | 1 | 2026 | 54 | 0.230 |
Why?
| | Vesico-Ureteral Reflux | 2 | 2016 | 38 | 0.220 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1322 | 0.220 |
Why?
| | Mitotic Index | 2 | 2015 | 25 | 0.220 |
Why?
| | Carcinoma, Papillary | 1 | 2025 | 79 | 0.220 |
Why?
| | Kidney Diseases | 1 | 2009 | 427 | 0.220 |
Why?
| | Hypertrophy | 2 | 2019 | 127 | 0.210 |
Why?
| | Genetic Predisposition to Disease | 5 | 2025 | 2365 | 0.210 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2197 | 0.210 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 970 | 0.210 |
Why?
| | Perioperative Care | 2 | 2024 | 231 | 0.210 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2013 | 421 | 0.210 |
Why?
| | Clinical Competence | 2 | 2025 | 1244 | 0.200 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2024 | 65 | 0.200 |
Why?
| | Adrenocortical Carcinoma | 1 | 2024 | 67 | 0.200 |
Why?
| | Gonadal Dysgenesis | 1 | 2023 | 7 | 0.200 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2024 | 177 | 0.190 |
Why?
| | Lymphocytes | 1 | 2025 | 382 | 0.190 |
Why?
| | Mast Cells | 1 | 2024 | 146 | 0.190 |
Why?
| | Tumor Suppressor Proteins | 1 | 2025 | 321 | 0.190 |
Why?
| | Pubic Bone | 1 | 2022 | 6 | 0.180 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2025 | 428 | 0.180 |
Why?
| | Monocytes | 1 | 2025 | 538 | 0.180 |
Why?
| | Urination | 1 | 2022 | 48 | 0.180 |
Why?
| | Algorithms | 1 | 2009 | 1839 | 0.170 |
Why?
| | Blood Platelets | 1 | 2025 | 400 | 0.170 |
Why?
| | Sertoli Cell Tumor | 1 | 2021 | 2 | 0.170 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2022 | 118 | 0.170 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 28 | 0.170 |
Why?
| | Aniridia | 1 | 2020 | 5 | 0.170 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1495 | 0.170 |
Why?
| | PAX6 Transcription Factor | 1 | 2020 | 21 | 0.170 |
Why?
| | Testosterone | 2 | 2015 | 419 | 0.160 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2021 | 46 | 0.160 |
Why?
| | Interleukin-2 | 1 | 2022 | 437 | 0.160 |
Why?
| | Codon, Nonsense | 1 | 2020 | 44 | 0.160 |
Why?
| | Pneumothorax | 1 | 2021 | 51 | 0.160 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2019 | 117 | 0.160 |
Why?
| | Reoperation | 3 | 2014 | 631 | 0.160 |
Why?
| | Eye Proteins | 1 | 2020 | 91 | 0.160 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1054 | 0.160 |
Why?
| | Penile Neoplasms | 1 | 2019 | 6 | 0.160 |
Why?
| | Priapism | 1 | 2019 | 10 | 0.160 |
Why?
| | Syndrome | 1 | 2021 | 380 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2024 | 2032 | 0.150 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2019 | 44 | 0.150 |
Why?
| | Patient Selection | 3 | 2013 | 719 | 0.150 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2019 | 19 | 0.150 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2019 | 8 | 0.150 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2019 | 10 | 0.150 |
Why?
| | Proportional Hazards Models | 3 | 2011 | 1325 | 0.150 |
Why?
| | Computers | 1 | 2019 | 67 | 0.150 |
Why?
| | Decision Trees | 1 | 2019 | 81 | 0.150 |
Why?
| | Genotype | 2 | 2016 | 1835 | 0.150 |
Why?
| | Neutrophils | 1 | 2025 | 1134 | 0.150 |
Why?
| | Puberty, Precocious | 1 | 2019 | 12 | 0.150 |
Why?
| | Dermatofibrosarcoma | 1 | 2018 | 7 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 732 | 0.140 |
Why?
| | Genetic Testing | 2 | 2019 | 482 | 0.140 |
Why?
| | Diagnostic Errors | 1 | 2019 | 175 | 0.140 |
Why?
| | Self-Examination | 1 | 2018 | 1 | 0.140 |
Why?
| | Proton Therapy | 1 | 2018 | 15 | 0.140 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 239 | 0.140 |
Why?
| | Animals | 6 | 2025 | 38109 | 0.130 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 189 | 0.130 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 222 | 0.130 |
Why?
| | Preoperative Period | 1 | 2018 | 149 | 0.130 |
Why?
| | Drug Utilization | 1 | 2018 | 167 | 0.130 |
Why?
| | Analysis of Variance | 2 | 2017 | 1311 | 0.130 |
Why?
| | Mutation | 1 | 2009 | 4099 | 0.130 |
Why?
| | Asymptomatic Diseases | 1 | 2018 | 102 | 0.130 |
Why?
| | Aged, 80 and over | 4 | 2019 | 8279 | 0.130 |
Why?
| | Unnecessary Procedures | 1 | 2017 | 54 | 0.130 |
Why?
| | Registries | 3 | 2025 | 2385 | 0.130 |
Why?
| | Ultrasonography, Doppler | 1 | 2018 | 126 | 0.130 |
Why?
| | Testis | 1 | 2018 | 163 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2025 | 927 | 0.130 |
Why?
| | Intraoperative Period | 1 | 2017 | 69 | 0.130 |
Why?
| | General Surgery | 1 | 2019 | 207 | 0.130 |
Why?
| | Europe | 1 | 2018 | 412 | 0.130 |
Why?
| | Logistic Models | 3 | 2018 | 2119 | 0.120 |
Why?
| | Mice | 3 | 2024 | 18365 | 0.120 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1253 | 0.120 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1416 | 0.120 |
Why?
| | Feasibility Studies | 2 | 2018 | 1095 | 0.120 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.120 |
Why?
| | North America | 1 | 2016 | 310 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 357 | 0.110 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 476 | 0.110 |
Why?
| | Certification | 1 | 2016 | 119 | 0.110 |
Why?
| | Translocation, Genetic | 2 | 2018 | 118 | 0.110 |
Why?
| | Models, Statistical | 1 | 2019 | 682 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1563 | 0.110 |
Why?
| | Learning | 1 | 2019 | 452 | 0.110 |
Why?
| | Phosphorylation | 1 | 2019 | 1733 | 0.110 |
Why?
| | History, 21st Century | 1 | 2015 | 219 | 0.110 |
Why?
| | Anaplasia | 2 | 2024 | 7 | 0.110 |
Why?
| | Matched-Pair Analysis | 1 | 2014 | 37 | 0.110 |
Why?
| | Forecasting | 1 | 2016 | 391 | 0.100 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2014 | 18 | 0.100 |
Why?
| | Genitalia, Female | 1 | 2014 | 42 | 0.100 |
Why?
| | TRPM Cation Channels | 1 | 2014 | 75 | 0.100 |
Why?
| | Ureteral Calculi | 1 | 2014 | 16 | 0.100 |
Why?
| | Kidney Function Tests | 1 | 2014 | 157 | 0.100 |
Why?
| | Inflammation | 1 | 2025 | 2880 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 427 | 0.100 |
Why?
| | Disease Management | 1 | 2017 | 647 | 0.100 |
Why?
| | Lipocalin-2 | 1 | 2013 | 79 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 947 | 0.090 |
Why?
| | Estrogens | 1 | 2015 | 380 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3869 | 0.090 |
Why?
| | Blood Vessels | 1 | 2014 | 171 | 0.090 |
Why?
| | Tissue Array Analysis | 1 | 2012 | 50 | 0.090 |
Why?
| | Spermatic Cord | 1 | 2012 | 1 | 0.090 |
Why?
| | Autophagy | 1 | 2014 | 286 | 0.090 |
Why?
| | Creatinine | 1 | 2014 | 506 | 0.090 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 289 | 0.090 |
Why?
| | Cohort Studies | 5 | 2016 | 5965 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 200 | 0.090 |
Why?
| | Radiation Dosage | 1 | 2013 | 193 | 0.090 |
Why?
| | Fetal Diseases | 1 | 2013 | 191 | 0.080 |
Why?
| | Surgical Wound Dehiscence | 1 | 2011 | 19 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2018 | 847 | 0.080 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 68 | 0.080 |
Why?
| | Cross-Sectional Studies | 2 | 2014 | 5872 | 0.080 |
Why?
| | Thrombectomy | 1 | 2011 | 78 | 0.080 |
Why?
| | Bevacizumab | 1 | 2011 | 167 | 0.080 |
Why?
| | Compliance | 1 | 2010 | 49 | 0.080 |
Why?
| | Texas | 1 | 2011 | 278 | 0.080 |
Why?
| | Rectum | 1 | 2011 | 180 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 529 | 0.080 |
Why?
| | Sulfonamides | 1 | 2014 | 581 | 0.080 |
Why?
| | Pyrroles | 1 | 2011 | 218 | 0.080 |
Why?
| | Referral and Consultation | 1 | 2016 | 853 | 0.080 |
Why?
| | Penis | 2 | 2019 | 32 | 0.070 |
Why?
| | Muscle, Smooth | 1 | 2010 | 153 | 0.070 |
Why?
| | Operative Time | 3 | 2014 | 175 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1054 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 783 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1257 | 0.070 |
Why?
| | Radiography | 1 | 2011 | 845 | 0.070 |
Why?
| | Alleles | 1 | 2011 | 881 | 0.070 |
Why?
| | Remission, Spontaneous | 2 | 2021 | 40 | 0.070 |
Why?
| | MicroRNAs | 1 | 2014 | 701 | 0.070 |
Why?
| | Pilot Projects | 1 | 2014 | 1890 | 0.070 |
Why?
| | Congenital Abnormalities | 1 | 2008 | 104 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2118 | 0.060 |
Why?
| | Indoles | 1 | 2011 | 501 | 0.060 |
Why?
| | Biomarkers | 2 | 2019 | 4275 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2014 | 3608 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2012 | 598 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2925 | 0.060 |
Why?
| | Pregnancy | 1 | 2018 | 7191 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 5233 | 0.060 |
Why?
| | Cystoscopy | 2 | 2016 | 21 | 0.060 |
Why?
| | Nephroma, Mesoblastic | 1 | 2025 | 2 | 0.060 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2024 | 15 | 0.050 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 988 | 0.050 |
Why?
| | Image-Guided Biopsy | 1 | 2024 | 41 | 0.050 |
Why?
| | Adrenalectomy | 1 | 2024 | 71 | 0.050 |
Why?
| | Nephroureterectomy | 1 | 2023 | 2 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1524 | 0.050 |
Why?
| | Sexual Development | 1 | 2023 | 16 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 331 | 0.050 |
Why?
| | Gonads | 1 | 2023 | 23 | 0.050 |
Why?
| | Lymphoma | 1 | 2024 | 233 | 0.050 |
Why?
| | Pancreatectomy | 1 | 2025 | 285 | 0.050 |
Why?
| | Analgesics, Opioid | 2 | 2024 | 1143 | 0.040 |
Why?
| | Germany | 1 | 2020 | 138 | 0.040 |
Why?
| | Accreditation | 1 | 2019 | 101 | 0.040 |
Why?
| | Hyperplasia | 1 | 2019 | 174 | 0.040 |
Why?
| | Mohs Surgery | 1 | 2018 | 29 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 26 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2024 | 783 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2018 | 323 | 0.030 |
Why?
| | Mosaicism | 1 | 2017 | 73 | 0.030 |
Why?
| | Ureteroscopy | 1 | 2016 | 16 | 0.030 |
Why?
| | Monitoring, Intraoperative | 1 | 2016 | 64 | 0.030 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 18 | 0.030 |
Why?
| | Caveolin 1 | 1 | 2014 | 20 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 557 | 0.030 |
Why?
| | Ureterostomy | 1 | 2014 | 2 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 252 | 0.030 |
Why?
| | Oncogenes | 1 | 2014 | 119 | 0.030 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 3 | 0.020 |
Why?
| | Cicatrix | 1 | 2014 | 69 | 0.020 |
Why?
| | Organ Size | 1 | 2014 | 463 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 688 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 476 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2014 | 744 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2011 | 28 | 0.020 |
Why?
| | Area Under Curve | 1 | 2011 | 331 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2011 | 309 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1990 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 205 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 380 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3192 | 0.020 |
Why?
| | Dihydrolipoamide Dehydrogenase | 1 | 2009 | 6 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1462 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2014 | 3550 | 0.020 |
Why?
|
|
Cost's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|